Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Spain and US build bridges in oncology R&D (research and development):

This article was originally published in Clinica

Executive Summary

Representatives of the top oncology institutes of Spain and the US met for the first time last week in Madrid to discuss plans to develop joint research projects. The Centro Nacional de Investigaciones Oncologicas (CNIO) and the National Cancer Institute (CNI) met with the common aim of "developing a research system that leads to the creation of new diagnostic and treatment methods and which encourages their prompt clinical application across the health system", said the Madrid-based CNIO. Referring to the recent advances in post-genome research, Miguel Angel Piris, director of the CNIO's molecular pathology programme, said that "much remains to be done, but the diagnosis and treatment of cancer is about to change in a radical way".

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT062772

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel